Evidence map›Paper›PMID 18190691›Full record

ArticleBreast cancer research : BCR2008

Na+/H+ exchanger regulatory factor 1 inhibits platelet-derived growth factor signaling in breast cancer cells.

Yong Pan, Edward J Weinman, Jia Le Dai

Open access · goldAbstract read
In one paragraph

Article in Breast cancer research : BCR, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.3field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Specificity of NHERF1 regulation of GPCR signaling and function in human airway smooth muscle.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Yong PanDepartment of Molecular Pathology, The University of Texas MD Anderson Cancer Center, Fannin Street, Houston, Texas 77054, USA.
Edward J Weinman
Jia Le Dai
Baltimore VA Medical Center · USThe University of Texas MD Anderson Cancer Center · USUniversity of Houston · US

Funding

UTMDACC SPORE in Breast CancerP50CA116199 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SAHIN, AYSEGUL · 2005 to 2009
$11.9M
SODIUM-H+ TRANSPORT IN RENAL APICAL MEMBRANESR01DK055881 · NIDDK · WEST VIRGINIA UNIVERSITY · PI WEINMAN, EDWARD J · 1999 to 2012
$4.6M
SYK SIGNALING AND BREAST CANCER INVASIONR01CA100278 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DAI, JIALE · 2003 to 2007
$1.3M
NCI NIH HHS P50 CA116199NCI NIH HHS P50-CA116199NCI NIH HHS R01 CA100278NCI NIH HHS R01-CA100278NIDDK NIH HHS R01 DK055881NIDDK NIH HHS R01-DK55881
6 · The paper itself

Abstract

introductionThe gene encoding Na+/H+ exchanger regulatory factor 1 (NHERF1) is a putative tumor suppressor gene that harbors frequent loss of heterozygosity (LOH) and intragenic mutations in breast carcinoma. The exact biologic activity of NHERF1 in mammary glands, however, remains unclear. It was recently proposed that NHERF1 forms a ternary complex with platelet-derived growth factor receptor (PDGFR) and phosphatase and tensin homolog (PTEN), linking NHERF1 suppressor activity to PDGF-initiated phosphoinositide-3 kinase (PI3K)/PTEN signaling.

methodsThe effect of NHERF1 on the kinetics of PDGF-induced Akt activation was determined in cells with varied NHERF1 background. Levels of active Akt in mammary gland of NHERF1 knockout and wild-type mice were compared. We also examined how NHERF1 expression status affects cell sensitivity to PDGFR inhibitor. A plausible connection between NHERF1 and PTEN pathway was explored at the genetic level.

resultsWe showed that NHERF1, through its PDZ-I domain, interacts directly with the carboxyl-terminal tail of PTEN. Knocking down NHERF1 expression in Zr75.1 cells markedly delayed the turnover of PDGF-induced phospho-Akt. Conversely, NHERF1 over-expression in MCF10A cells led to accelerated phospho-Akt degradation. The slowed decay of phospho-Akt that resulted from NHERF1 loss was evident in mouse embryonic fibroblasts isolated from NHERF1 knockout mice. In agreement with this, mammary gland tissues from these mice exhibited markedly elevated phospho-Akt. The responses of breast cancer cells to PDGFR inhibition were also altered by changes in NHERF1 expression level. Zr75.1 cells with NHERF1 knockdown were more resistant to STI-571-induced apoptosis than parental cells. Similarly, over-expression of NHERF1 rendered MCF10A cells more sensitive to STI-571. NHERF1-induced apoptotic response relies on an intact PTEN pathway; over-expression of NHERF1 in MCF10A cells with PTEN knockdown did not affect STI-571 sensitivity. It was found that NHERF1 LOH-positive breast cancer cells had reduced NHERF1 expression. Interestingly, these cells more frequently had wild-type PTEN or PI3KCA gene than the LOH-negative lines.

conclusionOur data indicate that the interaction of NHERF1 with PTEN counterbalances PI3K/Akt oncogenic signaling and may affect how cells respond to PDGFR inhibition in breast cancer. The dependence of NHERF1 responses on PTEN and genetic segregation of NHERF1 and PTEN (or PI3KCA) alterations suggest that NHERF1 is an active component of the PTEN pathway. Collectively, our study indicates that the biologic activity of NHERF1 in mammary gland is related to PTEN signaling.

Indexed as

AnimalsBreast NeoplasmsCell Line, TumorCell SurvivalFemaleMiceMice, KnockoutPhosphatidylinositol 3-KinasesPhosphoproteinsPlatelet-Derived Growth FactorPTEN PhosphohydrolaseSignal TransductionSodium-Hydrogen ExchangersPhosphatidylinositol 3-KinasesPhosphoproteinsPlatelet-Derived Growth FactorPTEN PhosphohydrolasePTEN protein, humansodium-hydrogen exchanger regulatory factorSodium-Hydrogen Exchangers

Identifiers

PMID18190691
PMCPMC2374956
OpenAlexW1965801617

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.